21 May 2013
Keywords: novartis, sebivo, gains, domestic, approval, swiss, drug
Article | 02 October 2006
Swiss drug major Novartis' Sebivo (telbivudine), a new treatment for patients with chronic hepatitis B, has been cleared in Switzerland.
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 October 2006
20 May 2013
© 2013 thepharmaletter.com